Search results for "Genetic enhancement"

showing 10 items of 101 documents

Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho–/– mouse

2015

As gene therapies for various forms of retinal degeneration progress toward human clinical trial, it will be essential to have a repertoire of safe and efficient vectors for gene delivery to the target cells. Recombinant adeno-associated virus (AAV) serotype 2/2 has been shown to be well tolerated in the human retina and has provided efficacy in human patients for some inherited retinal degenerations. In this study, the AAV2/8 and AAV2/rh10 serotypes have been compared as a means of gene delivery to mammalian photoreceptor cells using a photoreceptor specific promoter for transgene expression. Both AAV2/8 and AAV2/rh10 provided rescue of the retinal degeneration present in the rhodopsin kno…

Retinal degenerationlcsh:QH426-470TransgeneGenetic enhancementvirusesGene deliveryBiologyBioinformaticsArticlechemistry.chemical_compoundGeneticsmedicinelcsh:QH573-671Molecular BiologyRetinalcsh:CytologyRetinalmedicine.diseaseCell biologylcsh:Geneticsmedicine.anatomical_structurechemistryRhodopsinKnockout mousebiology.proteinMolecular MedicineCorrigendumMolecular Therapy. Methods & Clinical Development
researchProduct

New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia.

2021

: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder. The most common cause is a mutation in both alleles of the gene encoding for the low-density lipoprotein (LDL) receptor, although other causative mutations have been identified. Complications of atherosclerotic cardiovascular disease are common in these patients; therefore, reducing the elevated LDL-cholesterol burden is critical in their management. Conventionally, this is achieved by patients initiating lipid-lowering therapy, but this can present challenges in clinical practice. Fortunately, novel therapeutic strategies have enabled promising innovations in HoFH treatment. This review highlights recent and ongo…

Settore MED/09 - Medicina InternaGenetic enhancementHomozygous familial hypercholesterolemiaFamilial hypercholesterolemiaInclisiranBioinformaticsmedicine.disease_causeBenzimidazolePCSK9Hyperlipoproteinemia Type IIchemistry.chemical_compoundGene therapyAnticholesteremic AgentmedicineAngiopoietin-like 3HumansLow-density lipoprotein cholesterolAlleleAngiopoietin-like 3; Gene therapy; Gene-editing; Homozygous familial hypercholesterolemia; Inclisiran; Lomitapide; Low-density lipoprotein cholesterol; PCSK9MutationGene-editingAtherosclerotic cardiovascular diseasebusiness.industryPCSK9Anticholesteremic AgentsHomozygoteGenetic disorderGeneral MedicineCholesterol LDLmedicine.diseaseLomitapideLomitapidechemistrylipids (amino acids peptides and proteins)BenzimidazolesCardiology and Cardiovascular MedicinebusinessHumanHeart failure clinics
researchProduct

Overcoming the barrier of CD8+ T cells: Two types of nano-sized carriers for siRNA transport

2019

Abstract Bioengineering immune cells via gene therapy offers treatment opportunities for currently fatal viral infections. Also cell therapeutics offer most recently a breakthrough technology to combat cancer. These primary human cells, however, are sensitive to toxic influences, which make the utilization of optimized physical transfection techniques necessary. The otherwise commonly applied delivery agents such as LipofectamineⓇ or strongly cationic polymer structures are not only unsuitable for in vivo experiments, but are also highly toxic to immune cells. This study aimed to improve the design of polymeric carrier systems for small interfering RNA, which would allow efficient internali…

Small interfering RNAChemistrymedia_common.quotation_subjectGenetic enhancement0206 medical engineeringCellBiomedical Engineering02 engineering and technologyGeneral MedicineTransfection021001 nanoscience & nanotechnology020601 biomedical engineeringBiochemistryBiomaterialsImmune systemmedicine.anatomical_structuremedicineBiophysicsGene silencing0210 nano-technologyInternalizationCytotoxicityMolecular BiologyBiotechnologymedia_commonActa Biomaterialia
researchProduct

Application of fluorescence spectroscopy and multispectral imaging for non-invasive estimation of GFP transfection efficiency

2014

Electroporation and ultrasound induced sonoporation has been showed to induce plasmid DNA transfection to the mice tibialis cranialis muscle. It offers new prospects for gene therapy and cancer treatment. However, numerous experimental data are still needed to deliver the plausible explanation of the mechanisms governing DNA electro- or sono-transfection, as well as to provide the updates on transfection protocols for transfection efficiency increase. In this study we aimed to apply non-invasive optical diagnostic methods for the real time evaluation of GFP transfection levels at the reduced costs for experimental apparatus and animal consumption. Our experimental set-up allowed monitoring …

Tibialis Cranialisanimal structuresvirusesGenetic enhancementElectroporationfungiTransfectionBiologyMolecular biologyFluorescence spectroscopyCell biologyGreen fluorescent proteinchemistry.chemical_compoundchemistryembryonic structuresSonoporationDNASPIE Proceedings
researchProduct

Alpha-1 antitrypsin deficiency: outstanding questions and future directions

2018

BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition that leads to decreased circulating alpha-1 antitrypsin (AAT) levels, significantly increasing the risk of serious lung and/or liver disease in children and adults, in which some aspects remain unresolved. METHODS: In this review, we summarise and update current knowledge on alpha-1 antitrypsin deficiency in order to identify and discuss areas of controversy and formulate questions that need further research. RESULTS: 1) AATD is a highly underdiagnosed condition. Over 120,000 European individuals are estimated to have severe AATD and more than 90% of them are underdiagnosed. CONCLUSIONS: 2) Several clinical and…

Vasculitismedicine.medical_specialtyCirrhosisPanniculitisGenetic enhancementlcsh:MedicineReviewDisease03 medical and health sciencesLiver diseasePulmonary Disease Chronic Obstructive0302 clinical medicinealpha 1-Antitrypsin DeficiencymedicineCOPDAnimalsHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineRare respiratory diseasesGenetics (clinical)ReimbursementCOPDAlpha 1-antitrypsin deficiencybusiness.industrylcsh:RAugmentation therapyGeneral Medicinemedicine.diseaseAlpha-1 antitrypsinFibrosis030228 respiratory systemCirrhosisAlpha-1 antitrypsin deficiencyalpha 1-AntitrypsinEtiologySERPINA1business
researchProduct

Treatment of Anderson-Fabry Disease

2020

Fabry disease is an X-linked disorder of glycosphingolipid metabolism that results in progressive accumulation of neutral glycosphingolipids, predominantly globotriaosylsphingosine (Gb3) in lysosomes, as well as other cellular compartments of several tissues, causing multi-organ manifestations (acroparesthesias, hypohidrosis, angiokeratomas, signs and symptoms of cardiac, renal, cerebrovascular involvement). Pathogenic mutations lead to a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA). In the presence of high clinical suspicion, a careful physical examination and specific laboratory tests are required. Finally, the diagnosis of Fabry’s disease is confirmed by the demonstrat…

Viral vectorsMaleGenetic enhancementChaperone therapyPhysical examinationDiseaseKidneyViral vector03 medical and health sciencesGene therapy0302 clinical medicineDrug DiscoverymedicineHumansEnzyme Replacement Therapy030304 developmental biologyPharmacology0303 health sciencesmedicine.diagnostic_testbusiness.industryPharmacologicalGenetic TherapyEnzyme replacement therapymedicine.diseaseFabry diseasePharmacological chaperonealpha-GalactosidaseImmunologyFabry DiseaseFemaleStem cellbusiness030217 neurology & neurosurgerymedicine.drugCurrent Pharmaceutical Design
researchProduct

Efficient gene therapy based targeting system for the treatment of inoperable tumors

2012

Background A considerable percentage of tumors are not amenable to surgery. We have designed a simple and powerful targeting system that offers an alternative option for the multi-component pre-targeting strategies used clinically. This targeting system can be used for any type of solid tumors independent of the tumor type, thereby omitting the need to engineer unique antibodies for each specific application or tumour type. In the present study, we show the expression of a chimeric fusion protein, which contains the low-density lipoprotein receptor transmembrane domains and avidin, after local gene transfer and its ability to bind biotinylated compounds in vivo. Methods Semliki Forest virus…

biologyGenetic enhancementSemliki Forest virusbiology.organism_classificationmedicine.diseaseFusion proteinMolecular biologyTargeted drug deliveryIn vivoBiotinylationGliomaDrug DiscoveryGeneticsCancer researchmedicineMolecular MedicineMolecular imagingMolecular BiologyGenetics (clinical)The Journal of Gene Medicine
researchProduct

Gene Therapy of Human Melanoma. Immunization of Patients with Autologous Tumor Cells Admixed with Allogeneic Melanoma Cells Secreting Interleukin 6 a…

1995

biologybusiness.industryMelanomaGenetic enhancementCancermedicine.diseaseSoluble Interleukin 6 ReceptorImmunizationImmunologyGeneticsbiology.proteinmedicineMolecular MedicineHuman melanomaInterleukin 6businessMolecular BiologyAutologous tumorHuman Gene Therapy
researchProduct

Enzyme replacement and gene therapy for mucopolysaccharidoses: current progress and future directions

2015

Introduction: Mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes that are responsible for the stepwise degradation of complex carbohydrates, the glycosaminoglycans. Whereas in the past the treatment of MPS consisted mainly of palliative care, enzyme replacement therapy (ERT) is now possible for some MPS disorders, and in the future many other therapeutic options will become available.Areas covered: This review, based on personal experience and the currently available literature, will give an overview on the efficacy and limitations of ERT and will discuss new therapeutic approaches, such as anti-inflammatory drugs, substrate reduction therapy, ch…

congenital hereditary and neonatal diseases and abnormalitiesPalliative carebusiness.industryHealth PolicyGenetic enhancementmedicine.medical_treatmentnutritional and metabolic diseasesLysosomal storage disordersHematopoietic stem cell transplantationEnzyme replacement therapyBioinformaticsImmunologymedicinePharmacology (medical)Substrate reduction therapybusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)Expert Opinion on Orphan Drugs
researchProduct

Detection ofEPOgene doping in blood

2012

Gene doping--or the abuse of gene therapy--will continue to threaten the sports world. History has shown that progress in medical research is likely to be abused in order to enhance human performance. In this review, we critically discuss the progress and the risks associated with the field of erythropoietin (EPO) gene therapy and its applicability to EPO gene doping. We present typical vector systems that are employed in ex vivo and in vivo gene therapy trials. Due to associated risks, gene doping is not a feasible alternative to conventional EPO or blood doping at this time. Nevertheless, it is well described that about half of the elite athlete population is in principle willing to risk …

education.field_of_studybusiness.industryTransgeneGenetic enhancementPopulationPharmaceutical SciencePharmacologyBioinformaticsAnalytical ChemistryBlood dopingSubstance Abuse DetectionGene dopingErythropoietinEnvironmental ChemistryMedicineeducationbusinessGeneSpectroscopymedicine.drugDrug Testing and Analysis
researchProduct